

Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)

September 2014



View Report Details

Scope of the Report

The report titled "Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)" provides an insight into the glaucoma treatment market over the years with a special focus on major categories- pharmaceuticals and devices. The report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market. Further, companies like Pfizer Inc, Merck & Co, Allergan Inc and Alcon (Division of Novartis) are profiled in the report.

Segments Coverage

- ⊖ The US
- ⊖ Japan

Company Coverage

- ⊖ Pfizer Inc
- ⊖ Merck & Co
- ⊖ Allergan Inc
- ⊖ Alcon (Division of Novartis)

Executive Summary

Glaucoma, the second most common cause of blindness worldwide is generally characterized by relatively high intraocular pressure (IOP) as a result of impaired drainage of fluid, known as aqueous humor, from the eye. Currently approved treatments for glaucoma include a number of pharmaceutical drugs, laser therapies and surgical procedures. Glaucoma treatment forms a significant portion of the overall eye care market.

The market for glaucoma treatment has grown rapidly in the last decade, based on both increasing number of people with glaucoma and the introduction of new treatments. However, the worldwide glaucoma treatment market is expected to decline that can be attributable to price reduction of drugs due to generic availability of many brands in coming years.


The glaucoma pharmaceuticals are segmented into two classes namely prostaglandins analogues (PGAs) and Non PGAs that include beta blockers, carbonic anhydrase inhibitors and alpha agonists. PGAS are the most widely prescribed drug class for glaucoma with latanoprost (brand name Xalatan) the most commonly prescribed drug.

Key growth drivers of the market include rising ageing population, healthcare expenditures, medical coverage and new innovative combination drugs. The market players in medication as well as devices segments are totally different and somewhat very fragmented. Leaders in glaucoma medication space include Pfizer Inc, Alcon Inc. (Novartis), Allergan Inc and Merck and Co, Inc. Companies developing glaucoma drug-delivery devices include Ocular Therapeutix Inc, QLT Inc, pSivida Corp, Icon Bioscience Inc, Amorphex Therapeutics LLC, Euclid Systems Corp and Replenish Inc. In glaucoma laser market, top market leaders include Ellex, Lumenis, Quantel and Lightmed.


Global Glaucoma Treatment Market: An Overview

The worldwide glaucoma treatment market decreased from US\$.... billion in 2010 to US\$..... billion in 2013. The decline can be attributed to price reduction of drugs due to generic availability of many brands in coming years. Nearly million people are expected to develop glaucoma by 2020.

Global Glaucoma Treatment Market Sales in US\$ Billion, 2010-2013



Market Share of Commonly Prescribed Glaucoma Drugs in %, 2013




- Prostaglandins (PGA) are the most widely prescribed drug class for glaucoma. Beta blockers are the second most widely prescribed class for glaucoma and timolol (brand names Timoptic, Istalol, etc.) is the most widely prescribed beta blocker.


Global Glaucoma Devices Market

Worldwide sales of medical devices to diagnose and treat glaucoma were reported at US\$... million in 2013, an increase of% from 2008. The emergence of high-growth glaucoma devices based on minimally invasive surgical implants and introduction of new technologies are driving the sales.

Global Glaucoma Devices Market Size in US\$ Million, 2008-2013



Global Glaucoma Devices Market Segmentation in %, 2013



- The SUSD (Single Use Surgical Devices) category includes stents and implants, but these require invasive surgery. This segment accounted for ...% of glaucoma devices market followed by lasers (...%), surgical instruments (....%) and surgical systems (....%).